AI News Feed
Market watch
Apple Podcasts Subscriptions to Add Subscriber-Exclusive VideoGoogle Maps speedometer on Android Auto reported switching between MPH and KPHMicrosoft refreshes Surface Pro 12 and Surface Laptop 13 with Snapdragon X2 Plus, adds haptic Surface MouseApple Ships watchOS 27.0.1 to Fix Random Restarts on Apple Watch Series 12 and Ultra 4Developer Releases ForensicDbg, a Post-Mortem Debugger for Native Windows x64/x86 CrashesOpenAI and Anthropic CEOs Push for AI Cooperation at UN After Trump Rebuffs 'Globalist Scheme'
Apple Podcasts Subscriptions to Add Subscriber-Exclusive VideoGoogle Maps speedometer on Android Auto reported switching between MPH and KPHMicrosoft refreshes Surface Pro 12 and Surface Laptop 13 with Snapdragon X2 Plus, adds haptic Surface MouseApple Ships watchOS 27.0.1 to Fix Random Restarts on Apple Watch Series 12 and Ultra 4Developer Releases ForensicDbg, a Post-Mortem Debugger for Native Windows x64/x86 CrashesOpenAI and Anthropic CEOs Push for AI Cooperation at UN After Trump Rebuffs 'Globalist Scheme'
Products & Applications

Enveda raises $311M Series E to advance nature-derived AI drugs into clinical trials

Enveda raised $311 million at a $2 billion valuation to advance AI-discovered, nature-derived drugs into clinical trials.

AI News Feed · 2026-09-24 05:48

The round was led by Catalio Capital Management, with participation from Iconiq and other investors. The new valuation doubles the valuation Enveda reached 12 months ago.

Enveda’s premise is that powerful medicines can be harnessed from plants and microbes rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the discovery of these new drugs using AI and other techniques.

The startup is currently testing several drugs in patients. One targets severe skin conditions, and another is designed to help maintain weight loss after people stop taking GLP-1s.

Enveda is among a wave of companies advancing AI-discovered candidates into human clinical trials, even though AI has not yet produced any FDA-approved drugs.

The funding and valuation details were reported by TechCrunch AI, which said the Series E was led by Catalio Capital Management with participation from Iconiq and others. The report said the financing doubles Enveda’s valuation from 12 months earlier and that the company is testing multiple drugs in patients.

Editor's Summary

Enveda raised $311 million in a Series E led by Catalio Capital Management at a $2 billion valuation, doubling its valuation from 12 months earlier. The company is using AI to discover drugs from plants and microbes and is testing several candidates in patients, including treatments for severe skin conditions and weight-loss maintenance after GLP-1 use. The funding adds to a wave of AI-discovered drug candidates entering human trials, though no AI-discovered drug has received FDA approval.